Conde Sandro José, Luvizotto Renata de Azevedo Melo, Síbio Maria Teresa de, Saraiva Patrícia Pinto, Brentani Maria Mitzi, Nogueira Célia Regina
Departamento de Clínica Médica, Universidade Estadual Paulista "Júlio de Mesquista Filho", Botucatu, SP, Brasil.
Arq Bras Endocrinol Metabol. 2012 Jun;56(4):238-43. doi: 10.1590/s0004-27302012000400004.
The aim of this study was to determine thyroid hormone (TH) profile in postmenopausal patients with breast cancer (BC).
12 CaM patients stages I or II, without interventions that could interfere with tumor progression were selected, as well as and a control group with 18 postmenopausal women without CaM. We measured serum anti-thyroperoxidase antibody (TPOAB), thyroid-stimulating hormone (TSH), free thyroxine (T4L), estradiol (E2), follicle-stimulating hormone (FSH), and luteinizing hormone (LH), before and after surgery, besides immunohistochemistry for estrogen (ER) and progesterone (PR) receptors.
Four patients with CaM showed changes in thyroid hormone profile: two had hyperthyroidism, one hypothyroidism, and one was positive for TPO-AB. All of them positive for ER and PR. TSH levels in breast cancer patients were not different from levels found in the control group (1.89 ± 1.56 vs. 2.86 ± 3.12 mIU/mL), but the levels of T4L in patients with CaM were statistically higher than those of the control group (1.83 ± 0.57 vs. 1.10 ± 0.20 ng/dL).
These results reinforce the need for assessment of thyroid status in CaM patients, since in the absence of E2, changes in clinical HTs can act in E2-controlled processes.
